What's in Mucos Pharma GmbH & Co. KG's pipeline?

Mucos Pharma GmbH & Co. KG has 3 drugs in our index: 1 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Mucos Pharma GmbH & Co. KG's portfolio?

Top competitors by shared drug class: Dow University of Health Sciences.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/mucos-pharma-gmbh-co-kg.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Mucos Pharma GmbH & Co. KG — Portfolio Competitive Intelligence Brief

Mucos Pharma GmbH & Co. KG pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Wobenzym® plus	Wobenzym® plus	marketed	Proteolytic enzyme combination		Immunology / Inflammation
Phlogenzym	Phlogenzym	phase 3			Other

Therapeutic area mix

Immunology / Inflammation · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Dow University of Health Sciences · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Mucos Pharma GmbH & Co. KG:

Cite this brief

Drug Landscape (2026). Mucos Pharma GmbH & Co. KG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mucos-pharma-gmbh-co-kg. Accessed 2026-05-16.